Cabaletta Bio, Inc

(NASDAQ:CABA)

Latest On Cabaletta Bio, Inc (CABA):

Date/Time Type Description Signal Details
2023-05-18 16:00 ESTNewsCabaletta Bio up 1%, prices $87M offeringN/A
2023-05-18 02:29 ESTNewsCabaletta Bio commences underwritten public offering of sharesN/A
2023-05-16 23:33 ESTNewsCabaletta Bio jumps 16% as FDA clears trial for myositis candidateN/A
2023-05-11 15:27 ESTNewsCabaletta Bio GAAP EPS of -$0.45 beats by $0.02N/A
2023-05-01 18:20 ESTNewsCabaletta's potential lupus drug CABA-201 gets FDA fast track tagN/A
2023-04-28 03:16 ESTNewsCabaletta Bio: Speculative Biotech With OpportunityN/A
2023-03-31 16:02 ESTNewsCabaletta CAR T cell therapy for lupus gets FDA nod to enter trialN/A
2023-03-31 16:02 ESTNews4 stocks to watch on Friday: Amazon, Kraft Heinz, and moreN/A
2023-03-16 13:19 ESTNewsCabaletta Bio GAAP EPS of -$0.52 misses by $0.08N/A
2023-01-27 17:59 ESTNewsCabaletta rises as Morgan Stanley upgrades citing new CAR-T assetN/A
2023-01-25 12:46 ESTNewsCabaletta: Adding To Position For 36% Return Potential After CABA-201 Rally (Technical Analysis)N/A
2022-12-08 20:30 ESTNewsCabaletta Bio dips on announcing $35M offeringN/A
2022-11-10 11:40 ESTNewsCabaletta Bio GAAP EPS of -$0.39 beats by $0.09N/A
2022-08-30 16:03 ESTNewsCabaletta downgraded at Morgan Stanley on upcoming data for lead assetN/A
2022-08-11 21:46 ESTNewsCabaletta Bio GAAP EPS of -$0.45 beats by $0.05N/A
2022-05-18 20:14 ESTNewsCabaletta Bio updates Phase 1 interim data for lead assetN/A
2022-05-12 11:04 ESTNewsCabaletta Bio GAAP EPS of -$0.45N/A
2022-03-18 09:46 ESTNewsCabaletta Bio GAAP EPS of -$0.49 beats by $0.11N/A
2021-12-14 08:41 ESTNewsCabaletta Bio tanks 34% on cell therapy data in early-stage study for pemphigus vulgarisN/A
2021-11-01 14:01 ESTNewsCabaletta Bio EPS beats by $0.05N/A
2021-11-01 14:01 ESTNewsCabaletta rises as skin diseases drug shown to be safe in early data of phase 1 trialN/A
2021-08-19 00:00 ESTNewsCabaletta Bio reports results from DesCAARTes trial in patients with pemphigus vulgarisN/A
2021-08-05 20:25 ESTNewsCabaletta Bio EPS beats by $0.03N/A
2021-03-18 15:25 ESTAnalyst RatingThe Analyst Target Price has increased from $20.33 to $22.25.Buy
2021-03-18 07:46 ESTFinancialsCompany financials have been released.Neutral
2021-03-17 17:01 ESTNewsCabaletta Bio EPS misses by $0.04N/A
2021-03-17 15:39 ESTEarnings EstimateAn EPS average of -$0.46 is estimated for the quarter ending on June 30, 2021.Sell
2021-03-17 15:39 ESTEarnings EstimateAn EPS average of -$2.18 is estimated for the 2022 year.Sell
2021-01-20 12:58 ESTNewsCabaletta: DSG3-CAART's 1H 2021 Data Release Can Substantiate This Young BiotechN/A
2021-01-11 10:22 ESTAnalyst RatingThe Analyst Target Price has increased from $20 to $20.33.Buy
2021-01-09 03:37 ESTNewsChardan Capital initiates Cabaletta Bio with Buy ratingN/A
2020-12-10 06:47 ESTNewsDosing underway in Cabaletta Bio's DSG3-CAART study in a rare skin blistering disorderN/A
2020-12-04 06:26 ESTFinancialsCompany financials have been released.Neutral
2020-11-27 00:46 ESTFinancialsCompany financials have been released.Neutral
2020-11-24 15:51 ESTAnalyst RatingThe Analyst Target Price has decreased from $21.67 to $20.Neutral
2020-11-17 07:28 ESTFinancialsCompany financials have been released.Neutral
2020-11-14 23:46 ESTFinancialsCompany financials have been released.Neutral
2020-11-12 07:15 ESTFinancialsCompany financials have been released.Neutral
2020-11-11 09:52 ESTNewsCabaletta Bio EPS beats by $0.08N/A
2020-11-11 09:52 ESTNewsCabaletta Bio +5% on Q3 results, pipeline updateN/A
2020-11-11 06:54 ESTEarnings EstimateAn EPS average of -$0.44 is estimated for the quarter ending on March 31, 2021.Sell
2020-10-15 08:02 ESTNewsCabaletta Bio (CABA) Investor Presentation - SlideshowN/A
2020-10-14 11:22 ESTAnalyst RatingThe Analyst Target Price has decreased from $22.5 to $21.67.Neutral
2020-10-08 21:07 ESTFinancialsCompany financials have been released.Neutral
2020-10-04 15:25 ESTFinancialsCompany financials have been released.Neutral
2020-09-26 16:38 ESTFinancialsCompany financials have been released.Neutral
2020-09-17 09:18 ESTFinancialsCompany financials have been released.Neutral
2020-08-14 12:44 ESTFinancialsCompany financials have been released.Neutral
2020-08-10 03:29 ESTFinancialsCompany financials have been released.Neutral
2020-08-07 23:40 ESTFinancialsCompany financials have been released.Neutral

About Cabaletta Bio, Inc (CABA):

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also include MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. Cabaletta Bio, Inc. has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was founded in 2017 and is headquartered in Philadelphia, Pennsylvania.

CABA Quotes by TradingView

See Advanced Chart

General

  • Name Cabaletta Bio, Inc
  • Symbol CABA
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 31
  • Fiscal Year EndDecember
  • IPO Date2019-10-25
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Web URLhttp://www.cabalettabio.com
View More

Valuation

  • Price/Book (Most Recent Quarter) 2.23
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$2.13
  • Next Year EPS Estimate -$2.45
  • Next Quarter EPS Estimate -$0.42
  • Return on Assets -17%
  • Return on Equity -27%
  • Earnings Per Share -$0.94
  • Revenue Per Share $0
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 276.24 million
  • Analyst Target Price $22.25
View More

Share Statistics

  • Shares Outstanding 24.06 million
  • Shares Float 7.91 million
  • % Held by Insiders 523%
  • % Held by Institutions 67.4%
  • Shares Short 1.63 million
  • Shares Short Prior Month 1.61 million
  • Short Ratio 15.52
  • Short % of Float 8%
  • Short % of Shares Outstanding 7%
View More

Technicals

  • 52 Week High $16.38
  • 52 Week Low $6.07
  • 50 Day Moving Average 11.96
  • 200 Day Moving Average 12.4
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Cabaletta Bio, Inc (CABA) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Cabaletta Bio, Inc (CABA) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-16$N/A-$0.40-$0.36-11.11%
2020-09-302020-11-10$N/A-$0.36-$0.4418.18%
2020-06-302020-08-06$N/A-$0.35-$0.3910.26%
2020-03-312020-05-12$N/A-$0.33-$0.23-43.48%
2019-12-312020-03-30$N/A-$0.33-$0.4729.79%
2019-09-302019-12-05$N/A-$1.21-$2.2646.46%

Cabaletta Bio, Inc (CABA) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Cabaletta Bio, Inc (CABA) Chart:

Cabaletta Bio, Inc (CABA) News:

Below you will find a list of latest news for Cabaletta Bio, Inc (CABA) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Cabaletta Bio, Inc (CABA) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2025-07-180.50CALL0 00TRUE00
2025-07-1810.85CALL0 1582.84TRUE00
2025-07-181.50.37CALL0 68133.21TRUE00
2025-07-1820.07CALL6 3675100.14FALSE-0.03-0.3
2025-07-182.50.04CALL0 134117.14FALSE00
2025-07-1850.05CALL0 13446.13FALSE00
2025-07-187.50CALL0 10FALSE00
2025-07-180.50PUT0 0347.95FALSE00
2025-07-1810PUT0 0168.92FALSE00
2025-07-181.50.05PUT20 1481.11FALSE0.050
2025-07-1820.29PUT47 107154.57TRUE0.290
2025-07-182.50PUT0 0269.24TRUE00
2025-07-1850PUT0 00TRUE00
2025-07-187.50PUT0 00TRUE00
2025-08-150.50CALL0 7641.62TRUE00
2025-08-1511.29CALL0 28247.34TRUE00
2025-08-151.50.43CALL0 14149.96TRUE00
2025-08-1520.68CALL0 128241FALSE00
2025-08-152.50.08CALL5 1332111.01FALSE-0.02-0.2
2025-08-1550.05CALL0 1412186.76FALSE00
2025-08-157.50CALL0 287232.47FALSE00
2025-08-150.50PUT0 20231.31FALSE00
2025-08-1510.05PUT0 18112.54FALSE00
2025-08-151.50PUT0 30102.44FALSE00
2025-08-1520.42PUT47 491.65TRUE0.420
2025-08-152.50.65PUT0 49149.06TRUE00
2025-08-1550PUT0 1320TRUE00
2025-08-157.50PUT0 20TRUE00
2025-11-210.51.32CALL0 46154.86TRUE00
2025-11-2111.25CALL0 42266.29TRUE00
2025-11-211.50.59CALL0 111240.89TRUE00
2025-11-2120.42CALL0 26697.28FALSE00
2025-11-212.50.29CALL0 6550100.84FALSE00
2025-11-2150.1CALL107 890127.69FALSE0.10
2025-11-217.50.1CALL0 1432187.97FALSE00
2025-11-210.50PUT0 0135.59FALSE00
2025-11-2110.21PUT0 39117.01FALSE00
2025-11-211.50PUT0 51156.29FALSE00
2025-11-2120.63PUT0 4486.93TRUE00
2025-11-212.51.05PUT20 399115.14TRUE1.050
2025-11-2150PUT0 41126.93TRUE00
2025-11-217.55.6PUT0 2234.23TRUE00
2026-02-200.50CALL0 090.23TRUE00
2026-02-2010CALL0 0141.18TRUE00
2026-02-201.50.7CALL0 1083.77TRUE00
2026-02-2020.49CALL0 35127.24FALSE00
2026-02-202.50CALL0 0110.6FALSE00
2026-02-2050.35CALL0 10171.44FALSE00
2026-02-207.50CALL0 00FALSE00
2026-02-200.50PUT0 0263.16FALSE00
2026-02-2010PUT0 0217.41FALSE00
2026-02-201.50PUT0 0102.69FALSE00
2026-02-2020PUT0 088.76TRUE00
2026-02-202.50PUT0 083.89TRUE00
2026-02-2050PUT0 00TRUE00
2026-02-207.50PUT0 00TRUE00

Latest CABA Trades:

Date Shares Price
Jun 13, 2022 7:37 PM EST1$1.08
Jun 13, 2022 7:37 PM EST6$1.08
Jun 13, 2022 7:51 PM EST7$1.06
Jun 13, 2022 7:57 PM EST7$1.06
Jun 13, 2022 7:58 PM EST7$1.055

Cabaletta Bio, Inc (CABA) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312520159049/0001193125-20-159049-index.htm
2019-10-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319025941/0000899243-19-025941-index.htm
2019-10-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319025942/0000899243-19-025942-index.htm
2019-10-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319025943/0000899243-19-025943-index.htm
2019-10-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319025946/0000899243-19-025946-index.htm
2019-10-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319025947/0000899243-19-025947-index.htm
2019-10-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319026016/0000899243-19-026016-index.htm
2019-10-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319026017/0000899243-19-026017-index.htm
2019-10-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319026018/0000899243-19-026018-index.htm
2019-10-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319026020/0000899243-19-026020-index.htm
2019-10-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319026345/0000899243-19-026345-index.htm
2019-10-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319026346/0000899243-19-026346-index.htm
2020-02-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924320004509/0000899243-20-004509-index.htm
2020-02-135Annual statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924320004511/0000899243-20-004511-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924320006864/0000899243-20-006864-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924320006865/0000899243-20-006865-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924320006867/0000899243-20-006867-index.htm
2020-09-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924320025326/0000899243-20-025326-index.htm
2020-07-21SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1759138/000090266420002724/0000902664-20-002724-index.htm
2019-11-07SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1759138/000092963819000988/0000929638-19-000988-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1759138/000092963820000331/0000929638-20-000331-index.htm
2019-10-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000110465919056233/0001104659-19-056233-index.htm
2019-10-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000110465919057348/0001104659-19-057348-index.htm
2019-10-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000110465919058504/0001104659-19-058504-index.htm
2019-11-12SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1759138/000110465919061822/0001104659-19-061822-index.htm
2019-10-24S-1MEFRegistration adding securities to prior Form S-1 registration [Rule 462(b)]https://www.sec.gov/Archives/edgar/data/1759138/000119312519273939/0001193125-19-273939-index.htm
2019-10-25424B4Prospectus [Rule 424(b)(4)]https://www.sec.gov/Archives/edgar/data/1759138/000119312519274807/0001193125-19-274807-index.htm
2019-10-29S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1759138/000119312519277804/0001193125-19-277804-index.htm
2019-10-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312519278927/0001193125-19-278927-index.htm
2019-11-07SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1759138/000119312519287367/0001193125-19-287367-index.htm
2020-01-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312520005110/0001193125-20-005110-index.htm
2020-01-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312520017724/0001193125-20-017724-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1759138/000119312520038349/0001193125-20-038349-index.htm
2020-02-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312520042689/0001193125-20-042689-index.htm
2020-03-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312520090013/0001193125-20-090013-index.htm
2020-03-30S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1759138/000119312520091086/0001193125-20-091086-index.htm
2020-04-23DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1759138/000119312520115863/0001193125-20-115863-index.htm
2020-05-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312520134391/0001193125-20-134391-index.htm
2020-05-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312520139782/0001193125-20-139782-index.htm
2020-05-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312520153792/0001193125-20-153792-index.htm
2020-06-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312520159049/0001193125-20-159049-index.htm
2020-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312520211336/0001193125-20-211336-index.htm
2019-10-30SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1759138/000119380519001374/0001193805-19-001374-index.htm
2019-10-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000119380519001376/0001193805-19-001376-index.htm
2020-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1759138/000119380520000185/0001193805-20-000185-index.htm
2019-12-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1759138/000156459019045375/0001564590-19-045375-index.htm
2020-03-3010-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1759138/000156459020013929/0001564590-20-013929-index.htm
2020-05-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1759138/000156459020024508/0001564590-20-024508-index.htm
2020-08-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1759138/000156459020037278/0001564590-20-037278-index.htm
2019-10-24EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1759138/999999999519002384/9999999995-19-002384-index.htm

Cabaletta Bio, Inc (CABA) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Cabaletta Bio, Inc (CABA). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 523%
Institutional Ownership: 6740%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2019-10-295AM Ventures V, L.P.10% Share HolderBuy454,545.0011.004,999,995.00454,545.00https://www.sec.gov/Archives/edgar/data/1759138/000110465919058504/0001104659-19-058504-index.htm
2019-10-29James E Flynn10% Share HolderBuy700,000.0011.007,700,000.00700,000.00https://www.sec.gov/Archives/edgar/data/1759138/000119380519001376/0001193805-19-001376-index.htm